Elcatonin in combination with risedronate is more effective than risedronate alone for relieving back pain in postmenopausal women with osteoporosis

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 7, 2012, Pages 1159-1165

  Takakuwa, Masayuki ^a   Iwamoto, Jun ^b  

^a Takakuwa Orthopaedic Nagayama Clinic   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Back pain; Clinical vertebral fracture; Elcatonin; Postmenopausal woman; Risedronate

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; ELCATONIN; RISEDRONIC ACID;

ADULT; AGED; ANALGESIA; ARTICLE; BACKACHE; BODY MOVEMENT; BONE DENSITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEMUR NECK; FUNCTIONAL ASSESSMENT; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PATIENT COMPLIANCE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN URINE LEVEL; REST; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE;

AGED; AGED, 80 AND OVER; ANALGESICS; BACK PAIN; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCITONIN; COLLAGEN TYPE I; DRUG THERAPY, COMBINATION; ETIDRONIC ACID; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PAIN MEASUREMENT; PEPTIDES;

EID: 84863541661     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-00200     Document Type: Article

References (43)

1. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R, Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos. Int., 11, 83-91 (2000).
2. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD, Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA, 282, 1344-1352 (1999).
3. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY, Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. N. Engl. J. Med., 344, 333-340 (2001).
4. Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst. Rev., 23, CD004523 (2008).
5. Roux C, Seeman E, Eastell R, Adachi J, Jackson RD, Felsenberg D, Songcharoen S, Rizzoli R, Di Munno O, Horlait S, Valent D, Watts NB. Efficacy of risedronate on clinical vertebral fractures within six months. Curr. Med. Res. Opin., 20, 433-439 (2004).
6. Harrington JT, Ste-Marie LG, Brandi ML, Civitelli R, Fardellone P, Grauer A, Barton I, Boonen S. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif. Tissue Int., 74, 129-135 (2004).
7. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther., 296, 235-242 (2001).
8. Morikawa T, Munekata E, Sakakibara S, Noda T, Otani M. Synthesis of eel-calcitonin and (asu1,7)-eel-calcitonin: contribution of the disulfide bond to the hormonal activity. Experientia, 32, 1104-1106 (1976).
9. Otani M, Kitazawa S, Yamaguchi H, Meguro T, Orimo H. Biological activity of (asu1,7)-eel-calcitonin. Clin. Med., 20, 2217-2222 (1978), in Japanese.
10. Orimo H. The development of a novel therapy for bone disease, the discovery of elcatonin. (Christiansen C, Overgard K eds.), Osteoporosis. Handelstrykkeriet, Aalborg, pp. 2091-2095 (1990).
11. Yamamoto I, Morita R, Fukunaga M, Dokoh S, Shigeno C, Torizuka K, Noda T. Adenylate cyclase activation and competitive binding with renal tissue using synthetic eel calcitonin analog and its fragments. Endocrinology, 108, 698-702 (1981).
12. Ishida Y, Kawai S. Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in post-menopausal women with osteoporosis: The Yamaguchi Osteoporosis Prevention Study. Am. J. Med., 117, 549-555 (2004).
13. Asahi-Kasei Co. Ltd. "Outline of the results of a clinical trial of intramuscular elcatonin 20S.": 〈http://www.asahi-kasei.co.jp/asahi/jp/ news/2003/pdf/me030606.pdf〉. January 26th, 2012.
14. Yoh K, Tanaka K, Ishikawa A, Ishibashi T, Uchino Y, Sato Y, Tobinaga M, Hasegawa N, Kamae S, Yoshizawa M. Health-related quality of life (HRQOL) in Japanese osteoporotic patients and its improvement by elcatonin treatment. J. Bone Miner. Metab., 23, 167-173 (2005).
15. Ikegami S, Kamimura M, Uchiyama S, Nakagawa H, Hashidate H, Takahara K, Takahashi J, Kato H. Anti-nociceptive effects of elcatonin injection for postmenopausal women with back pain: a randomized controlled trial. Open Orthop. J., 4, 132-136 (2010).
16. American Academy of Orthopaedic Surgeons. "Clinical Practice Guidelines.": 〈http://www.aaos.org/Research/guidelines/guide. asp〉. January 26th, 2012.
17. Ohtori S, Akazawa T, Murata Y, Kinoshita T, Yamashita M, Nakagawa K, Inoue G, Nakamura J, Orita S, Ochiai N, Kishida S, Takaso M, Eguchi Y, Yamauchi K, Suzuki M, Aoki Y, Takahashi K. Risedronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures. J. Clin. Neurosci., 17, 209-213 (2010).
18. Iwamoto J, Makita K, Sato Y, Takeda T, Matsumoto H. Alendronate is more effective than elcatonin in improving pain and quality of life in postmenopausal women with osteoporosis. Osteoporos. Int., 22, 2735-2742 (2011).
19. Orimo H, Sugioka Y, Fukunaga M, Muto Y, Hotokebuchi T, Gorai I, Nakamura T, Kushida K, Tanaka H, Ikai T, Oh-hashi Y. Diagnostic criteria of primary osteoporosis. J. Bone Miner. Metab., 16, 139-150 (1998).
20. Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-Hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H; Osteoporosis Diagnostic Criteria Review Committee: Japanese Society for Bone and Mineral Research. Diagnostic criteria for primary osteoporosis: year 2000 revision. J. Bone Miner. Metab., 19, 331-337 (2001).
21. Orimo H, Morii H, Inoue T, Yamamoto K, Minaguchi H, Ishii Y, Morita K, Fujimaki E, Watanabe R, Harada S, Honjo H, Fujita T. Effect of elcatonin on involutional osteoporosis. J. Bone Miner. Metab., 14, 73-78 (1996).
22. Fukunaga M, Kushida K, Kishimoto H, Shiraki M, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H, Risedronate Phase III Research Group. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. Osteoporos. Int., 13, 971-979 (2002).
23. Kishimoto H, Fukunaga M, Kushida K, Shiraki M, Itabashi A, Nawata H, Nakamura T, Ohta H, Takaoka K, Ohashi Y, Risedronate Phase III Research Group. Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen. J. Bone Miner. Metab., 24, 405-413 (2006).
24. Sriwatanakul K, Kelvie W, Lasagna L, Calimlim JF, Weis OF, Mehta G. Studies with different types of visual analog scales for measurement of pain. Clin. Pharmacol. Ther., 34, 234-239 (1983).
25. Roland M, Fairbank J. The Roland-Morris disability questionnaire and the oswestry disability questionnaire. Spine (Phila Pa 1976), 25, 3115-3124 (2000).
26. Roland MO, Morris RW. A study of the natural history of back pain. Part I: development of a reliable and sensitive measure of disability in low-back pain. Spine, 8, 141-144 (1983).
27. Suzukamo Y, Fukuhara S, Kikuchi S, Konno S, Roland M, Iwamoto Y, Nakamura T, Committee on Science Project, Japanese Orthopaedic Association. Validation of the Japanese version of the Roland-Morris disability questionnaire. J. Orthop. Sci., 8, 543-548 (2003).
28. Shibata K, Takeda M, Ito A, Takeda M, Sagai H. Ovariectomy-induced hyperalgesia and antinociceptive effect of elcatonin, a synthetic eel calcitonin. Pharmacol. Biochem. Behav., 60, 371-376 (1998).
29. Martin MI, Goicoechea C, Ormazabal MJ, Lopez F, Alfaro MJ. Analgesic effect of two calcitonins and in vitro interaction with opioids. Gen. Pharmacol., 26, 641-647 (1995).
30. Ito A, Kumamoto E, Takeda M, Shibata K, Sagai H, Yoshimura M. Mechanisms for ovariectomy-induced hyperalgesia and its relief by calcitonin: participation of 5-HT1A-like receptor on C-afferent terminals in substantia gelatinosa of the rat spinal cord. J. Neurosci., 20, 6302-6308 (2000).
31. Iwamoto J, Uzawa M, Sato Y, Takeda T, Matsumoto H. Effects of short-term combined treatment with alendronate and elcatonin on bone mineral density and bone turnover in postmenopausal women with osteoporosis. Ther. Clin. Risk Manag., 5, 499-505 (2009).
32. Kawate H, Ohnaka K, Adachi M, Kono S, Ikematsu H, Matsuo H, Higuchi K, Takayama T, Takayanagi R. Alendronate improves QOL of postmenopausal women with osteoporosis. Clin. Interv. Aging, 5, 123-131 (2010).
33. Agarwala S, Sule A, Pai BU, Joshi VR. Alendronate in the treatment of avascular necrosis of the hip. Rheumatology (Oxford), 41, 346-347 (2002).
34. Gangji V, Appelboom T. Analgesic effect of intravenous pamidronate on chronic back pain due to osteoporotic vertebral fractures. Clin. Rheumatol., 18, 266-267 (1999).
35. Glover D, Lipton A, Keller A, Miller AA, Browning S, Fram RJ, George S, Zelenakas K, Macerata RS, Seaman JJ. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. Cancer, 74, 2949-2955 (1994).
36. Hortobagyi GN, Terhiault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H. S6imeone JF, Seaman J, Knight RD. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N. Engl. J. Med., 335, 1785-1791 (1996).
37. Siris ES, Chines AA, Altman RD, Brown JP, Johnston CC Jr, Lang R, McClung MR, Mallette LE, Miller PD, Ryan WG, Singer FR, Tucci JR, Eusebio RA, Bekker PJ. Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. J. Bone Miner. Res., 13, 1032-1038 (1998).
38. Brown MF, Hukkanen MV, McCarthy ID, Redfern DR, Batten JJ, Crock HV, Hughes SP, Polak JM. Sensory and sympathetic innervation of the vertebral endplate in patients with degenerative disc disease. J. Bone Joint Surg. Br., 79, 147-153 (1997).
39. Hartman JM, Berger A, Baker K, Bolle J, Handel D, Mannes A, Pereira D, St Germain D, Ronsaville D, Sonbolian N, Torvik S, Calis KA, Phillips TM, Cizza G, P.O.W.E.R. (Premenopausal, Osteoporosis, Women, Alendronate, Depression) Study Group. Quality of life and pain in premenopausal women with major depressive disorder: the POWER study. Health Qual. Life Outcomes, 18, 2 (2006).
40. Ohtori S, Inoue G, Koshi T, Ito T, Watanabe T, Yamashita M, Yamauchi K, Suzuki M, Doya H, Moriya H, Takahashi Y, Takahashi K. Sensory innervation of lumbar vertebral bodies in rats. Spine (Phila Pa 1976), 32, 1498-1502 (2007).
41. Ohtori S, Inoue G, Koshi T, Ito T, Yamashita M, Yamauchi K, Suzuki M, Doya H, Moriya H, Takahashi Y, Takahashi K. Characteristics of sensory dorsal root ganglia neurons innervating the lumbar vertebral body in rats. J. Pain, 8, 483-488 (2007).
42. Bianchi M, Franchi S, Ferrario P, Sotgiu ML, Sacerdote P. Effects of the bisphosphonate ibandronate on hyperalgesia, substance P, and cytokine levels in a rat model of persistent inflammatory pain. Eur. J. Pain, 12, 284-292 (2008).
43. Orita S, Ohtori S, Koshi T, Yamashita M, Yamauchi K, Inoue G, Suzuki M, Eguchi Y, Kamoda H, Arai G, Ishikawa T, Miyagi M, Ochiai N, Kishida S, Takaso M, Aoki Y, Toyone T, Takahashi K. The effects of risedronate and exercise on osteoporotic lumbar rat vertebrae and their sensory innervation. Spine, 35, 1974-1982 (2010).